荣昌生物(09995.HK) 公布2024年度业绩快报,按中国会计准则,实现营业总收入17.15亿人民币(下同),按年增加58.4%,主要受惠注射用泰它西普和注射用维迪西妥单抗销量增加。亏损由上年度15.11亿元,收窄至14.68亿元,每股亏损2.73元。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/10/29 | 第三季业绩 | 无派息 |
2024/08/16 | 中期业绩 | 无派息 |
2024/04/26 | 第一季业绩 | 无派息 |
2024/03/27 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.